HC Wainwright Has Pessimistic Outlook of MIST Q1 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Equities research analysts at HC Wainwright reduced their Q1 2025 EPS estimates for Milestone Pharmaceuticals in a research note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.17) per share for the quarter, down from their prior estimate of ($0.16). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($0.99) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.46 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04.

Milestone Pharmaceuticals Stock Performance

Shares of Milestone Pharmaceuticals stock opened at $2.00 on Wednesday. The business’s 50 day moving average price is $1.97 and its 200 day moving average price is $1.67. The company has a market cap of $106.66 million, a price-to-earnings ratio of -2.47 and a beta of 1.78. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. Milestone Pharmaceuticals has a one year low of $1.12 and a one year high of $2.75.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Valeo Financial Advisors LLC grew its holdings in shares of Milestone Pharmaceuticals by 100.0% in the third quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock valued at $30,000 after purchasing an additional 10,000 shares during the period. PVG Asset Management Corp acquired a new position in Milestone Pharmaceuticals in the 3rd quarter valued at about $46,000. Atria Investments Inc boosted its holdings in Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after purchasing an additional 12,430 shares during the last quarter. Finally, BML Capital Management LLC grew its stake in shares of Milestone Pharmaceuticals by 3.0% in the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock valued at $1,727,000 after buying an additional 33,196 shares during the period. Hedge funds and other institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.